An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Completed · Phase 1/Phase 2

Conditions studied: Prostate Cancer, Tumors

In brief

To determine the feasibility and safety of administering YM155 in combination with docetaxel

Key facts

Study ID

NCT00514267

Run by

Astellas Pharma Inc

People needed

32

Starts

2007-05-01

Expected to finish

2010-03-01

Last updated by the study team

2015-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Part 1:
• Male subjects with histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiological evidence of metastatic disease.
• Part 2:
• Subjects with histologically and cytologically confirmed solid tumors with measurable disease (except HRPC).

You may not qualify if…

• Radiation therapy within 4 weeks of the start of study drug

Where it is running

• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.